Skip to main content
Addgene

pCDH-puro-myr-HA-Akt1
(Plasmid #46969)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 46969 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    PCDH-CMV-MCS-EF1-PURO
  • Backbone manufacturer
    System Biosciences
  • Backbone size w/o insert (bp) 7384
  • Vector type
    Mammalian Expression, Lentiviral
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    Stbl3
  • Copy number
    Unknown

Gene/Insert

  • Gene/Insert name
    AKT1
  • Alt name
    v-akt murine thymoma viral oncogene homolog 1__
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    1500
  • Entrez Gene
    AKT1 (a.k.a. AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA)
  • Promoter CMV
  • Tags / Fusion Proteins
    • myr (N terminal on insert)
    • HA (N terminal on insert)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site XbaI (not destroyed)
  • 3′ cloning site EcoRI (not destroyed)
  • 5′ sequencing primer CMV-F
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Myr-HA-Akt1 was amplified by PCR from pcDNA3-HA-Myr-Akt1 (Addgene plasmid #9008) and subcloned into the XbaI and EcoRI sites of the pCDH-CMV-MCS-EF1-Puro lentiviral vector.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pCDH-puro-myr-HA-Akt1 was a gift from Jialiang Wang (Addgene plasmid # 46969 ; http://n2t.net/addgene:46969 ; RRID:Addgene_46969)
  • For your References section:

    Inhibition of BET bromodomain targets genetically diverse glioblastoma. Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S, Wang J. Clin Cancer Res. 2013 Apr 1;19(7):1748-59. doi: 10.1158/1078-0432.CCR-12-3066. Epub 2013 Feb 12. 10.1158/1078-0432.CCR-12-3066 PubMed 23403638